12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eteplirsen: Additional Phase IIb data

Additional data from 10 patients aged 7-13 with DMD in the modified intent-to-treat (mITT) population of the open-label Study 4658-US-202 extension of the double-blind, U.S. Phase IIb Study 4658-US-201 trial showed that patients who received either dose of eteplirsen for 96 weeks (30 or 50 mg/kg) had a 6.3 m reduction in mean 6MWT from baseline to week 96 compared to a 74.1 m mean reduction for patients who received placebo for 24 weeks followed by eteplirsen for an additional 72 weeks (p<=0.004). Sarepta said 1 patient in the placebo/delayed eteplirsen treatment group suffered a broken ankle unrelated to treatment and was unable to perform the 6MWT at week 84. However, the patient did perform the test at week 96. The company said his walking...

Read the full 602 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >